骨折联络服务与老年髋部骨折患者死亡率:前瞻性队列研究
该前瞻性队列研究纳入724例60岁以上髋部骨折患者,比较实施骨折联络服务(FLS)前后各一年(2016年1月至2017年12月)的1年死亡率和再骨折率。FLS实施后抗骨质疏松药物处方率显著提高(74.9% vs 12.3%,p<0.01),但1年死亡率(20.2% vs 25.8%,p=0.07)和再骨折率(4.6% vs 3.6%,p=0.50)无显著差异。在FLS背景下接受抗骨质疏松药物治疗的患者较FLS实施前管理的患者1年死亡率更低(校正HR 0.66;95%CI 0.47-0.94;p<0.05)。
要点
- FLS实施后抗骨质疏松药物处方率显著提高(74.9% vs 12.3%,p<0.01)。
- FLS实施前后1年死亡率无显著差异(20.2% vs 25.8%,p=0.07)。
- FLS背景下接受抗骨质疏松药物治疗者1年死亡率低于FLS实施前管理者(校正HR 0.66;95%CI 0.47-0.94;p<0.05)。
核心结论
- FLS实施前后髋部骨折患者1年死亡率无显著差异。
- FLS的应用未影响发生第二次骨质疏松性骨折的风险。
- 在FLS背景下接受抗骨质疏松药物治疗的患者较FLS实施前管理的患者死亡率更低。
研究设计与样本
- 前瞻性队列研究,纳入60岁以上髋部骨折患者,比较FLS实施前(2016年1月至2017年12月间连续两年)与实施后各一年。
- 共纳入724例患者,FLS实施前357例,实施后367例,随访1年。
- 采用多因素Cox比例风险模型比较两组死亡率和再骨折率。
主要发现
- FLS实施后抗骨质疏松药物处方率显著高于实施前(275例(74.9%)vs 44例(12.3%);p<0.01)。
- FLS实施后1年死亡74例(20.2%),实施前死亡92例(25.8%),差异无统计学意义(p=0.07)。
- FLS实施后再骨折17例(4.6%),实施前再骨折13例(3.6%),差异无统计学意义(p=0.50)。
- FLS实施后接受抗骨质疏松药物治疗的患者较FLS实施前管理的患者(无论是否接受抗骨质疏松药物治疗)1年死亡率更低(校正HR 0.66;95%CI 0.47-0.94;p<0.05)。
临床怎么用
- 作者指出,在FLS背景下接受抗骨质疏松药物治疗与较低的死亡率相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Osteoporosis is a metabolic disorder that results in increased bone fragility and risk of fractures. Hip fracture is the most important fragility fracture. Fracture Liaison Service (FLS) is a secondary prevention model which identifies patients at risk for fragility fractures. The introduction of an intensive FLS model could decrease 1-year-mortality of hip fracture patients. INTRODUCTION: Hip fractures are a clinical manifestation of osteoporosis, and these patients are at risk of premature death and suffering subsequent fractures. FLS is an approach for secondary facture prevention by identifying patients with fragility fractures and initiating the appropriate treatment. Our objective is to analyze the effect of the FLS model over the first-year mortality rates following a hip fracture. METHODS: We conducted a prospective cohort study on patients over 60 years of age who suffered a hip fracture during two consecutive years, before and after the implementation of the FLS in our center (i.e., between January 2016 and December 2017). Patients' information was withdrawn from our local computerized database. Patients were followed for 1 year after the hip fracture. Mortality and re-fracture rates were compared between the two groups using a multivariate Cox proportional hazard model. RESULTS: A total of 724 individuals were included in this study (i.e., 357 before FLS implementation and 367 after FLS implementation). Anti-osteoporotic drugs were more frequently prescribed after FLS implementation [275 (74.9%) vs 44 (12.3%); p < 0.01]. A total of 74 (20.2%) patients after FLS implementation and 92 (25.8%) individuals before FLS implementation (p = 0.07) died during the follow-up period. A second fracture occurred in 17 (4.6%) patients after FLS implementation and 13 (3.6%) individuals before FLS implementation (p = 0.50). Patients who were treated with anti-osteoporotic drugs after the implementation of the FLS protocol had a lower 1-year mortality compared with patients managed before the implementation of the FLS protocol (treated or not treated with anti-osteoporotic drugs) [adjusted hazard ratio (HR) 0.66; 95% confidence interval (CI) 0.47-0.94; p < 0.05]. CONCLUSIONS: We did not observe significant 1-year-mortality differences following a hip fracture between patients treated before the implementation of an FLS protocol and patients treated after its implementation. The application of the FLS did not affect the risk of suffering a second osteoporotic fracture. However, patients treated with anti-osteoporotic drugs in an FLS context had a lower mortality rate compared with patients managed before the implementation of the FLS. LEVEL OF CLINICAL EVIDENCE: 2.
引用
- González-Quevedo D, Bautista-Enrique D, Pérez-Del-Río V, et al. Fracture liaison service and mortality in elderly hip fracture patients: a prospective cohort study. Osteoporos Int. 2019. PMID: 31511912. doi:10.1007/s00198-019-05153-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。